Company news

Atossa Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

April 9, 2025

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

March 24, 2025

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

March 19, 2025

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

March 10, 2025

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

February 4, 2025

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

January 29, 2025

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

January 22, 2025

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

January 5, 2025

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

December 11, 2024

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

December 10, 2024

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

December 9, 2024

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

December 8, 2024

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

November 20, 2024

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

November 19, 2024

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

November 11, 2024

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

November 4, 2024

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

November 3, 2024

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

October 30, 2024

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

October 20, 2024

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

October 13, 2024

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

September 30, 2024

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

September 9, 2024

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

August 27, 2024

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

August 20, 2024

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

August 19, 2024

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

August 11, 2024

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

July 21, 2024

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

July 1, 2024

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

June 27, 2024

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

June 16, 2024

Atossa to Present at the Sidoti Small-Cap Investor Conference

June 4, 2024

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

May 27, 2024

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

May 14, 2024

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 12, 2024

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

May 6, 2024

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

April 28, 2024

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

April 14, 2024

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

April 10, 2024

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

April 8, 2024

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

March 31, 2024

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

March 18, 2024

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

March 17, 2024

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

March 11, 2024

Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

March 5, 2024

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

February 21, 2024

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

February 6, 2024

Atossa Therapeutics Issues Letter to Shareholders

January 8, 2024

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

December 3, 2023

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

November 19, 2023

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 9 decks. Every deck is listed under its year.